139 related articles for article (PubMed ID: 35734243)
1. Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database.
Husni ME; Chang E; Broder MS; Paydar C; Bognar K; Desai P; Klyachkin Y; Khilfeh I
Open Access Rheumatol; 2022; 14():123-132. PubMed ID: 35734243
[TBL] [Abstract][Full Text] [Related]
2. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
3. Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use.
Kaplan D; Husni E; Chang E; Broder MS; Paydar C; Bognar K; Yan J; Richter S; Desai P; Khilfeh I
J Comp Eff Res; 2022 Jun; 11(8):575-582. PubMed ID: 35514324
[No Abstract] [Full Text] [Related]
4. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
Wu JJ; Pelletier C; Ung B; Tian M
Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
[No Abstract] [Full Text] [Related]
5. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
Wu JJ; Pelletier C; Ung B; Tian M
J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
[TBL] [Abstract][Full Text] [Related]
7. Racial and Ethnic Disparities in Treatment Initiation Among Patients with Newly Diagnosed Psoriatic Arthritis: A Retrospective Medicaid Claims Database Study.
Patel AA; Ferrante SA; Lin I; Fu AZ; Campbell AK; Tieng A
Rheumatol Ther; 2023 Oct; 10(5):1241-1253. PubMed ID: 37453020
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis.
Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
J Comp Eff Res; 2019 Jul; 8(9):699-709. PubMed ID: 31081676
[No Abstract] [Full Text] [Related]
9. Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis.
Dommasch ED; Kim SC; Lee MP; Gagne JJ
JAMA Dermatol; 2019 Oct; 155(10):1142-1152. PubMed ID: 31075163
[TBL] [Abstract][Full Text] [Related]
10. The risk of treated anxiety and treated depression among patients with psoriasis and psoriatic arthritis treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database.
Vasilakis-Scaramozza C; Persson R; Hagberg KW; Jick S
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1755-1763. PubMed ID: 31981426
[TBL] [Abstract][Full Text] [Related]
11. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
George MD; Baker JF; Ogdie A
J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
[TBL] [Abstract][Full Text] [Related]
12. Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.
Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
J Comp Eff Res; 2021 Aug; 10(12):989-998. PubMed ID: 34187202
[No Abstract] [Full Text] [Related]
13. Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis.
Kaplan DL; Ung BL; Pelletier C; Udeze C; Khilfeh I; Tian M
Clinicoecon Outcomes Res; 2020; 12():369-377. PubMed ID: 32765022
[TBL] [Abstract][Full Text] [Related]
14. Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Analyses from a Large US Claims Database.
Hur P; Kim N; Dai D; Piao OW; Zheng JZ; Yi E
Drugs Real World Outcomes; 2021 Mar; 8(1):29-38. PubMed ID: 33179146
[TBL] [Abstract][Full Text] [Related]
15. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
[TBL] [Abstract][Full Text] [Related]
16. The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.
Beukelman T; Xie F; Baddley JW; Chen L; Mannion ML; Saag KG; Zhang J; Curtis JR
Arthritis Res Ther; 2016 Sep; 18(1):210. PubMed ID: 27655411
[TBL] [Abstract][Full Text] [Related]
17. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
18. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
[TBL] [Abstract][Full Text] [Related]
19. Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic.
Das AK; Chang E; Paydar C; Broder MS; Orroth KK; Cordey M
Dermatol Ther (Heidelb); 2023 Sep; 13(9):1973-1984. PubMed ID: 37392261
[TBL] [Abstract][Full Text] [Related]
20. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
